ProofPilot, the leading end-to-end clinical experience platform, announced on September 15, 2025, its acquisition of Lokavant, the clinical trial intelligence company and premier provider of predictive analytics for clinical research. This strategic acquisition combines ProofPilot's trial execution capabilities with Lokavant's advanced analytics to create an integrated platform designed to optimize clinical research and accelerate new therapy delivery.
Strategic Integration of AI-Powered Analytics
Lokavant, spun out of Roivant in 2020, brings sophisticated technology that leverages historical and real-time data to deliver predictive insights, optimize study feasibility, and mitigate operational risk in study conduct. The integration enables sponsors and contract research organizations (CROs) to build and execute complex clinical trial experiences while anticipating challenges before they occur.
"ProofPilot has long demonstrated a commitment to empowering sponsors and research teams with the tools they need to execute successful trials," said Chris Venezia, CEO of ProofPilot. "By bringing Lokavant's predictive analytics engine into our platform, we're equipping our customers with an industry first ability to measure and predict success in real time by combining study stakeholder behaviors and real time study data."
Enhanced Platform Capabilities
The combined platform delivers a comprehensive data-driven approach to trial management with an intuitive experience for clinical researchers. Key features include AI-powered study forecasting that supports proactive scenario planning, integrated recruitment campaign management with real-time performance dashboards, and continuous monitoring capabilities during study execution.
The platform also incorporates study oversight capabilities that enhance data quality and compliance through site training driven by emerging site protocol adherence and data quality signals. This integration aims to improve operational predictability, reduce risk, and ensure trials generate reliable results.
Proven Performance Metrics
Lokavant's flagship solution, Spectrum, demonstrates significant operational improvements for clinical teams. The AI-powered platform enables independent forecasting of enrollment timelines and operational risk assessment both before and during study execution. Powered by advanced AI models including generative AI, machine learning, and causal AI, Lokavant delivers real-time forecasts with over 80% confidence in minutes.
According to the company, sponsors and CROs using Spectrum have achieved a 70% reduction in non-conformance events, 70x improvement in forecasting accuracy, and significant cuts in study timelines and costs.
Industry Impact and Vision
"We are excited to see Lokavant join forces with ProofPilot," said Alex Gasner, EVP Roivant Health. "This move aligns deeply with Roivant's mission—to improve the lives of patients by accelerating the development and commercialization of medicines that matter. By combining Lokavant's powerful, data-driven insights with ProofPilot's trial experience platform, biopharma will be better positioned to deliver innovative medicines and technologies faster, more precisely, and with greater impact for patients everywhere."
Rohit Nambisan, CEO & Co-Founder of Lokavant, emphasized the transformative potential of the merger: "By combining ProofPilot's innovative trial platform with Lokavant's predictive analytics, we are giving sponsors and CROs unprecedented clarity and foresight into study performance. Together, we empower them to plan smarter, adapt faster, and bring new therapies to patients more efficiently—setting a new standard for how clinical trials are designed and executed."
Market Position and Future Outlook
With this acquisition, ProofPilot strengthens its position as a market leader in clinical trial innovation, offering a fully integrated, end-to-end platform that combines digital trial planning, execution, and predictive intelligence to maximize operational performance. The platform focuses on simplifying site operations and reducing patient burden while deploying seamless, branded experiences from recruitment through close out.
The acquisition represents a significant step toward addressing the clinical research industry's need for greater predictability and efficiency in trial execution, potentially accelerating the delivery of innovative therapies to patients worldwide.
